Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
There is no data on safety and efficacy of a second course of ibritumomab tiuxetan. In this work, data on patients with B-cell NHL who were treated with two courses of ibritumomab tiuxetan were analyzed. Eighteen such patients were analyzed (age: 58 years, 48 - 91), with a median of four prior regimens (1 - 7), stem cell transplantation (n = 5), and radiation therapy (n = 6). After the first course, G3/4 neutropenia and thrombocytopenia was 35% and 41%; overall response rate (ORR) was 89%; time between courses was 16.6 months (6.0 - 42.7). After the second course, the incidence of G3/4 neutropenia and thrombocytopenia was 28% and 44%; and ORR 77%. There were no infectious or bleeding complications, secondary myelodysplastic syndromes, or leukemias. Retreatment with the ibritumomab tiuxetan regimen was well tolerated, with a safety profile similar to that of the first course. To conclude, patients who benefited from the first course of ibritumomab tiuxetan can benefit from retreatment.
Shah
Jatin
J
Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA.
Wang
Wenquan
W
Harrough
V Douglas
VD
Saville
Wayne
W
Meredith
Ruby
R
Shen
Sui
S
Mueh
John
J
Lister
John
J
Jasthy
Sri
S
Maggass
Gregory
G
McKay
Charles
C
Krumdieck
Richard
R
Tharp
Morgan
M
Winter
Christine
C
Gregory
Stephanie
S
Buchholz
William
W
Awasthi
Sanjay
S
Jacobs
Samuel
S
Chung
Harold
H
Egner
James
J
Lobuglio
Albert F
AF
Forero
Andres
A
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy; D012189:Retrospective Studies; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*